Management of thrombosis in women with antiphospholipid syndrome

Clinical Obstetrics and Gynecology

Volumn 44, Issue 1, 2001, Pages 36-47

  Chandramouli, Nitin B ^a,b   Rodgers, George M ^a  

^a ARUP LABORATORIES   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN DERIVATIVE; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; RALOXIFENE; TAMOXIFEN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; COMORBIDITY; DISEASE ASSOCIATION; DRUG SAFETY; HORMONE SUBSTITUTION; HUMAN; PATIENT MONITORING; REVIEW; RISK FACTOR; THROMBOSIS;

ACUTE DISEASE; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CHRONIC DISEASE; COMORBIDITY; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HEPARIN; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE; RISK FACTORS; THROMBOSIS;

EID: 0035137006     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200103000-00006     Document Type: Review

References (46)

1. International consensus statement on preliminary classification for definite antiphospholipid syndrome
2. Pathogenesis of the antiphospholipid antibody syndrome
3. Obstetric outcome in antiphospholipid syndrome
4. Antiphospholipid syndrome as a second cause of non-tumorous Budd-Chiari syndrome
5. CT features of abdominal manifestations of primary antiphospholipid syndrome
6. Superior sagittal sinus thrombosis associated with primary antiphospholipid syndrome: Case report
7. Primary antiphospholipid syndrome as a cause of intestinal infarction
8. Antiphospholipid antibodies and thrombosis
9. Criteria for the diagnosis of lupus anticoagulants: An update
10. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome
11. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standardization and quantitation of results
12. 2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients
13. Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases
14. A prospective epidemiological study on the occurrence of antiphospholipid antibody: The Montpellier Antiphospholipid (MAP) study
15. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
16. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
17. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
18. Low molecular weight heparin vs heparin in the treatment of patients with pulmonary embolism
19. Antithrombotic therapy for venous thromboembolic disease
20. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs. intravenous heparin. An economic analysis
21. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy
22. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin
23. Low-molecular-weight heparins in pregnancy
24. Low-molecular weight heparin during pregnancy and delivery. Preliminary experience with 41 pregnancies
25. Low-molecular-weight heparin for obstetric thromboprophylaxis. Experience of 69 pregnancies in 61 women at high-risk
26. Thromboprophylaxis with low molecular weight heparin (Dalteparin) in pregnancy
27. A comparison of three months anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
28. Management of thrombosis and pregnancy loss in the antiphospholipid syndrome
29. A retrospective review of 61 patients with antiphospholipid syndrome
30. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients
31. The management of thrombosis in the antiphospholipid-antibody syndrome
32. Thrombosis and antiphospholipid syndrome. A preliminary assessment of three antithrombotic treatments
33. Antiphospholipid antibodies and venous thromboembolism
34. Treatment of antiphospholipid syndrome in pregnancy
35. Bone density changes in pregnant women treated with heparin: A prospective, longitudinal study
36. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (fragmin) in patients with venous thromboembolism and contraindications to coumarin
37. Hemorrhagic complications of long-term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome
38. Massive ovarian hemorrhage complicating oral anticoagulation in the antiphospholipid syndrome: A report of three cases
39. Tamoxifen and risk of idiopathic venous thromboembolism
40. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
41. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study
42. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
43. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism
44. Risk of venous thromboembolism in users of hormone replacement therapy
45. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism
46. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the more randomized trial, multiple outcomes of raloxifene evaluation